These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15205830)

  • 1. [Eliminating alanine aminotransferase (ALT) determination in screening of blood components for transfusion and plasma for fractionation. At the 52nd Meeting of the Blood Professional Circle 1 October 2003 the following vote (V30) was delivered].
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2004 Jan; 47(1):82. PubMed ID: 15205830
    [No Abstract]   [Full Text] [Related]  

  • 2. [GPT limit values in blood donors: lower, higher or eliminate completely?].
    Caspari G; Gerlich WH
    Infusionsther Transfusionsmed; 1995 Jun; 22(3):142-4. PubMed ID: 7640508
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-transfusion hepatitis and serum alanine aminotransferase in blood donors.
    N Engl J Med; 1981 Aug; 305(7):403-4. PubMed ID: 6789203
    [No Abstract]   [Full Text] [Related]  

  • 4. Serum alanine aminotransferase (ALT) assay and incidence of posttransfusion non-A,non-B hepatitis.
    Barcena Marugan R; Zamora C; Moreno A; Erdozain Sosa JC; Perez Hernandez F; Lopez San Roman A
    Transfusion; 1989 Oct; 29(8):751. PubMed ID: 2508279
    [No Abstract]   [Full Text] [Related]  

  • 5. NAT screening of blood and plasma donations: evolution of technology and regulatory policy.
    Tabor E; Epstein JS
    Transfusion; 2002 Sep; 42(9):1230-7. PubMed ID: 12430684
    [No Abstract]   [Full Text] [Related]  

  • 6. [Alanine aminotransferase (ALAT, GPT): a reevaluation of exclusion limits for blood donors].
    Grunenberg R; Banik N; Krüger J
    Infusionsther Transfusionsmed; 1995 Jun; 22(3):145-51. PubMed ID: 7640509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alanine aminotransferase and posttransfusion hepatitis.
    Lacher DA
    JAMA; 1987 Feb; 257(8):1048. PubMed ID: 3100827
    [No Abstract]   [Full Text] [Related]  

  • 8. Abnormal alanine aminotransferase level in blood units from donors in Montreal does not indicate high risk of transmitting hepatitis.
    Steinbrecher UP; Kovacs TO; Gelly A; Tourigny M
    Clin Invest Med; 1983; 6(4):327-30. PubMed ID: 6671363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence, persistence and liver enzyme levels of HGV RNA-positive blood donors determined by large-scale screening and transmission by blood components.
    Hitzler WE; Runkel S
    Clin Lab; 2004; 50(1-2):25-31. PubMed ID: 15000218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should donor blood be screened for elevated alanine aminotransferase levels? A cost-effectiveness analysis.
    Silverstein MD; Mulley AG; Dienstag JL
    JAMA; 1984 Nov 23-30; 252(20):2839-45. PubMed ID: 6436522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Note on the measurement of alanine aminotransferase in the screening of blood donors.
    Dorizzi RM; Schiavon R; Disperati A; Chiavolini P; Capuzzo E
    Vox Sang; 1992; 62(4):246-7. PubMed ID: 1642006
    [No Abstract]   [Full Text] [Related]  

  • 12. Donor transaminase and recipient hepatitis. Impact on blood transfusion services.
    Alter HJ; Purcell RH; Holland PV; Alling DW; Koziol DE
    JAMA; 1981 Aug; 246(6):630-4. PubMed ID: 6788964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum alanine aminotransferase of donors in relation to the risk of non-A,non-B hepatitis in recipients: the transfusion-transmitted viruses study.
    Aach RD; Szmuness W; Mosley JW; Hollinger FB; Kahn RA; Stevens CE; Edwards VM; Werch J
    N Engl J Med; 1981 Apr; 304(17):989-94. PubMed ID: 6782484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Screening of blood donors for the prevention of non-A, non-B hepatitis].
    Seidl S
    Dtsch Med Wochenschr; 1983 Jan; 108(4):123-4. PubMed ID: 6402351
    [No Abstract]   [Full Text] [Related]  

  • 15. Posttransfusion hepatitis: clinical features, risk and donor testing.
    Alter HJ
    Prog Clin Biol Res; 1985; 182():47-61. PubMed ID: 3929262
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical aspects and risk factors in posttransfusion hepatitis].
    Realdi G; Tremolada F; Chiappetta F; Antona C; Noventa F; Loreggian M; Chemello L; Alberti A
    Ric Clin Lab; 1984; 14 Suppl 1():17-35. PubMed ID: 6330858
    [No Abstract]   [Full Text] [Related]  

  • 17. [Alanine aminotransferase is a substitute marker of viral hepatitis].
    Zhiburt EB
    Vopr Virusol; 2005; 50(6):18-20. PubMed ID: 16408624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proper donor screening--a good prevention of transfusion transmitted AIDS and hepatitis.
    Chatterjee K
    J Acad Hosp Adm; 1994 Jul; 6(2):49-52. PubMed ID: 10537998
    [No Abstract]   [Full Text] [Related]  

  • 19. [Usefulness of transaminase determination in transfusional practice].
    Gota F; Lombardi A
    Arch Sci Med (Torino); 1980; 137(1):127-9. PubMed ID: 7458645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we be screening blood donors for hepatitis G virus? The case for screening.
    Moaven LD
    Med J Aust; 1998 Oct; 169(7):373-4. PubMed ID: 9803250
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.